The whole ship has been steered away to the easier path for revenue and whatever other reasons they have decided to go that way….. If there was a true case to completely wipe out AML and beat Doxo I am sure RAC would go this way but you are up against the FDA cartel where you are given very poor subjects to treat and your data above stating 50% CR and 70% ORR just is not true for you trials run to date for RAC which is why people are here
Pulling up old 80s data does nothing to excite me! The cardiovascular protection does but see the cost of it is where I draw my questions moving forward. The orphan drug status is for the back up plan if it fails heart protection or a competitor comes in cheaper than $20k a pop
As for CF33 in vitro wipe all cancer cell lines but for now it is still in trials for combination therapy still kicking goals but this isn’t the thread for that…
RAC Price at posting:
$1.83 Sentiment: None Disclosure: Not Held
(20min delay)